CLAIMS

1. A ready to dilute liquid pharmaceutical composition comprising (i) a peptide epoxy ketone; (ii) a solvent system comprising one or more water miscible pharmaceutically acceptable organic solvents suitable for injection, and optionally water; and (iii) a non-volatile sugar acid.
2. A pharmaceutical composition according to Claim 1, wherein the peptide epoxy ketone is a proteasome inhibitor.
3. A pharmaceutical composition according to Claim 2, wherein the peptide epoxy ketone is carfilzomib.
4. A pharmaceutical composition according to Claim 1, wherein the composition comprises one or more pharmaceutically acceptable excipients selected from buffers, surfactants, antioxidants, preservatives, isotonicity agents and lyoprotectant agents.
5. A pharmaceutical composition according to Claim 1, wherein the non-volatile sugar acid is derived from a monosaccharide or a disaccharide.
6. A pharmaceutical composition according to Claim 1, wherein the non-volatile sugar acid is selected from lactobionic acid, glycolic acid, malic acid, citric acid, lactic acid, mandelic acid, and tartaric acid.
7. A pharmaceutical composition according to Claim 1, wherein the water miscible pharmaceutically acceptable solvent is selected from ethanol, propylene glycol, polyethylene glycol, glycerol, dimethylacetamide, N-methylpyrrolidone, dimethylsulfoxide, and mixtures thereof.
8. A pharmaceutical composition according to Claim 8, wherein the water miscible pharmaceutically acceptable solvent is selected from ethanol, propylene glycol, polyethylene glycol, and mixtures thereof.
9. A pharmaceutical composition according to Claim 5, comprising an anionic, nonionic, cationic or amphoteric surfactant.
10. A pharmaceutical composition according to Claim 10, comprising a nonionic surfactant selected from fatty alcohol acid or amide ethoxylates, monoglyceride ethoxylates, sorbitan ester ethoxylates, alkyl polyglycosides, and mixtures thereof.
11. A pharmaceutical composition according to Claim 10, wherein the nonionic surfactant is a polyoxyethylene derivative of a polyol ester (1) derived from (a) a fatty acid containing from about 8 to about 22 carbon atoms, and (b) a polyol selected from sorbitol, sorbitan, glucose, α-methyl glucoside, polyglucose having an average of

about 1 to about 3 glucose residues per molecule, glycerine, pentaerythritol and mixtures thereof; (2) containing an average of from about 10 to about 120oxyethylene units; and (3) having an average of about 1 to about 3 fatty acid residues per mole of polyoxyethylene derivative of polyol ester.

12. A pharmaceutical composition according to Claim 11, wherein the nonionic surfactant is selected from PEG-80, sorbitan laurate, and Polysorbate 80.
13. A pharmaceutical composition according to Claim 1, wherein the concentration of the peptide epoxy ketone is from about 0.1 to about 3.0 mg/mL when the composition is in a ready to use formulation.
14. A pharmaceutical composition according to Claim 1, wherein the water miscible pharmaceutically acceptable organic solvent suitable for injection comprises more than about 25% by volume of the total amount of liquid used to formulate the pharmaceutical composition.
15. A pharmaceutical composition according to Claim 14, wherein the water miscible pharmaceutically acceptable organic solvent suitable for injection comprises more than about 50% by volume of the total amount of liquid used to formulate the pharmaceutical composition.
16. A composition according to Claim 1, packaged in a container suitable for single or multi-use.
17. A composition according to Claim 16, wherein the container is an ampoule, a vial, a pre-filled syringe or an intravenous bag.